Vedolizumab effect on liver biochemistry in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease .
Phase of Trial: Phase IV
Latest Information Update: 01 Feb 2018
Price : $35 *
At a glance
- Drugs Vedolizumab (Primary)
- Indications Inflammatory bowel diseases; Primary sclerosing cholangitis
- Focus Therapeutic Use
- 01 Feb 2018 New trial record
- 29 Jan 2018 Results published in the Alimentary Pharmacology and Therapeutics.